Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anadolu Univ. MAO-B compound 2t
- Development stage
- Unknown
- Lead developer
- Anadolu University
01
Overview
Anadolu Univ. MAO-B compound 2t: sourced facts only. name: "The results showed that compound 2j potently inhibited MAO-A and MAO-B, while compound 2t strongly and selectively inhibited MAO-B compared to standard drugs." [PMID:34998057]; target: "The results showed that compound 2j potently inhibited MAO-A and MAO-B, while compound 2t strongly and selectively inhibited MAO-B compared to standard drugs." [PMID:34998057]; developer: "Anadolu University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 26470, Eskişehir, Turkey; Bilecik Şeyh Edebali University, Vocational School of Health Services, Department of Pharmacy Services, 11000, Bilecik, Turkey. Electronic address: [email protected]." [PMID:34998057]
02
Targets
MAOB (Monoamine oxidase B)
Beyond the preview
Go deeper on Anadolu Univ. MAO-B compound 2t.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anadolu Univ. MAO-B compound 2t.